Skip to main content
. 2013 Jul 30;14(1):79. doi: 10.1186/1465-9921-14-79

Table 1.

Patient characteristics at the year 1 assessment: data is presented for all patients and sub-divided by exacerbation category in year 1 of follow-up

  All COPD (n=1832) FE (n=543) IE (n=1289) p-value FE v IE
Age (years)
64 (7)
64 (7)
64 (7)
0.751
Females (%)
35%
41%
32%
<0.001
BMI (kg/m2)
27 (6)
26 (6)
27 (6)
0.006
Active smoker (%)
36%
33%
37%
0.113
*FEV1 (L)
1.37 (0.55)
1.14 (0.45)
1.47 (0.55)
<0.001
*FEV1 %predicted
49 (16)
43 (16)
52 (16)
<0.001
*FEV1/FVC %
45 (12)
41 (12)
46 (12)
<0.001
6-minute walk distance (m)
385 (123)
350 (119)
399 (122)
<0.001
%predicted 6MWD
74 (24)
69 (23)
77 (23)
<0.001
Blood oxygen saturation (%)
94.7 (2.9)
94.2 (3.1)
94.9 (2.8)
<0.001
Emphysema LAA% (-950HU)
18 (12)
20 (13)
17 (12)
<0.001
mMRC Dyspnoea Score
1.7 (1.1)
2.0 (1.1)
1.5 (1.0)
<0.001
SGRQ-C Total Score
47 (21)
57 (18)
43 (21)
<0.001
BODE Index
3.0 (2.1)
3.9 (2.2)
2.7 (2.0)
<0.001
White blood cells (10^9/L)
7.6 (2.2)
8.1 (2.4)
7.4 (2.0)
<0.001
Platelets (10^9/L)
266 (71)
276 (75)
261 (69)
0.002
Fibrinogen (mg/dL)
436 [383–504]
468 [405–535]
426 [376–492]
<0.001
CRP (mg/dL)
3.3 [1.5-7.3]
4.1 [1.8-9.1]
3.1 [1.4-6.6]
<0.001
SP-D (ng/mL)
119 [87–163]
115 [86–159]
121 [87–166]
0.294
PARC/CCL-18 (ng/mL)
112 [87–145]
119 [92–154]
111 [85–141]
0.001
Neutrophils (10^9/L)
5.0 (1.9)
5.4 (2.2)
4.8 (1.8)
<0.001
Treated with ICSL %
71%
81%
66%
0.159
Treated with LAMA %
63%
68%
60%
<0.001
Treated with ICS %
17%
15%
17%
0.336
Treated with LABA %
14%
14%
15%
0.813
Treated with Oxygen %
10%
16%
6%
<0.001
PPPY COPD Hosp. Year 1
0.20
0.55
0.05
<0.001
PPPY OCS only exbs Y1
0.13
0.35
0.04
<0.001
Diabetes
10%
8%
10%
0.287
Cardiovascular (excl. HTN)
33%
32%
33%
0.868
Reflux/heartburn
26%
33%
23%
<0.001
Anxiety
16%
21%
14%
<0.001
Depression symptoms 25% 33% 21% <0.001

P-values are for comparisons between patients with Frequent (FE) and Infrequent exacerbations (IE). Mean (SD) or Median [25% - 75% percentile].